

Moderate to Severe Atopic Dermatitis BNSSG Recommended Commissioning Pathway


The choice of treatment should be made on an individual basis, between the patient and clinician. Individual patient characteristics and risk factors should be taken into account. If treatments are found to be equally suitable for the patient the drug with the lowest overall costs should be used. This is reflected in this pathway document.

Has the patient tried the following treatments or are these contraindicated or not tolerated?

- emollients and topical corticosteroids (NICE TA81) (first line)
- topical calcineurin inhibitors, e.g. topical tacrolimus and pimecrolimus (NICE TA82) (second line)
- phototherapy – narrow band UVB (third line)

Has the disease not responded to at least 1 other systemic therapy, or these are contraindicated or not tolerated:

- Ciclosporin (licenced)
- Methotrexate (unlicensed)
- Azathioprine (unlicensed)
- Mycophenolate mofetil (unlicensed)



Abrocitinib oral (TA814) ± topical corticosteroids
Upadacitinib oral (TA814) ± topical corticosteroids
Baricitinib oral (TA681) ± topical corticosteroids
Dupilumab SC (TA534) ± topical corticosteroids
Tralokinumab SC (TA814) ± topical corticosteroids

For adults in whom there is an inadequate response to a second biological drug, seek supra-specialist advice from a clinician with expertise in biological therapy.